Over 100 California Auctions End Today - Bid Now
Over 2400 Total Lots Up For Auction at Three Locations - TN 02/23, NJ Cleansweep 02/29, TX 03/01

My interviews with Doug Beinborn, Peter Webner, Richard Fabian and Diku Mandavia

by Philip F. Jacobus, CEO | October 07, 2020
Clock-wise from top left: Doug Beinborn, Peter Webner, Richard Fabian and Dr. Diku Mandavia
Five Minutes in Healthcare is where I discuss current events with some of the industry's most influential leaders, as well as innovative thinkers who are working to meet the challenges of the coronavirus pandemic.

Over the last week I have had the pleasure of speaking to Doug Beinborn, Peter Webner, Richard Fabian and Diku Mandavia. Each interview is approximately five minutes long, or a few minutes over five.

In this installment, I check in with Doug Beinborn, associate principal in strategic supplier partnerships with Vizient, to discuss implantable devices and the benefits of cardiac remote monitoring for patients, as well as healthcare providers.

This is a topic of special interest to Doug, and he has written about it in our magazine. In July he contributed a byline looking at how COVID-19 tipped the scales in favor of remote cardiac monitoring.

Earlier, he provided an article provided a good introduction to remote cardiac monitoring, which is a great place to start if you want to continue learning after watching the interview.

In this installment, I check in with Peter Webner, CEO of Zionexa US, a French-American biotech company producing a PET tracer for breast cancer called Cerianna, which was approved in May and will be launched in early 2020 in partnership with PETNET Solutions.

We discuss how the PET agent works, and how it is poised to improve breast cancer outcomes. Full prescribing information for Cerianna (fluoroestradiol F18) injection is available at https://www.cerianna.com/wp-content/uploads/2020/05/cerianna-prescribing-information.pdf

In this installment, I check in with Richard Fabian, president and CEO of Fujifilm Sonosite, and Diku Mandavia, CMO for Fujifilm Sonosite, to discuss the company's FDA approval for using point-of-care ultrasound for COVID-19, the diagnostic value it brings to the pandemic, and what the road to regulatory approval looked like.

I initially spoke to Dr. Mandavia back in May about the role of point-of-care ultrasound in the pandemic, and since then the technology has continued to prove advantageous.

We hope you enjoy the videos. Please tell us what you think, and let us know who you would like to see interviewed next!

Back to HCB News

View all The Jacobus Report Blog Posts

About Phil Jacobus

Phil Jacobus has been involved in health care since 1977, when he visited China to sell equipment. He has done business in 35 countries and still travels extensively. Phil is active in charity, helps rural clinics and always tries to help DOTmed users when he can.

Phil is a member of AHRA, HFMA, AAMI and the Cryogenic Society of America. He has contributed to a number of magazines and journals and has addressed trade groups.

Phil's proudest achievement is that he has been happily married to his wife Barbara since 1989, who helped him found DOTmed in 1998.

You Must Be Logged In To Post A Comment